Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Specimen Handling 3Cisplatin 3Magnetic Resonance Spectroscopy 2Letrozole 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1ruxolitinib 1rozanolixizumab 1pyrotinib 1pirtobrutinib 1olutasidenib 1obinutuzumab 1niraparib 1naldemedine 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1enfortumab vedotin 1darolutamide 1dabrafenib 1cabozantinib 1apalutamide 1adacel 1acalabrutinib 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lutetium × 30 days × Clear all
NCT05803941 2026-06-04

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis

Phase 4 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡